Everything below concerns G protein-coupled receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Free base; the drug product is formulated as an acetate salt |
| Molar mass | About 1025 g/mol | Calculated for the free base |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| CAS Registry Number | 189691-06-3 | Common listing for the free base |
| Typical storage | -20 °C, desiccated, protected from light | Repeated freeze-thaw cycles are best avoided |
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
An insulin pump allows the replacement of slow-acting insulin for basal needs with a continuous infusion of rapid-acting insulin. The insulin pump delivers a single type of rapid-acting insulin in two ways:
According to contemporaries:most of the farmers, who are not sufficiently educated, follow mechanically and without reflection, the practice of their small township or the method of their old relatives. A new culture would require a tiring study. [...] But in vain would one cultivate, in vain would one multiply this salutary commodity, if the people themselves, if the poorest citizens, stubborn of an absurd prejudice, refused, disdained to consume it. We have seen them, in times of the cruellest famine, rejecting the potato with fury, and shouting that we wanted to poison them. (French: la plupart des cultivateurs, trop peu instruits, suivent machinalement et sans réflexions, la pratique de leur petit canton ou la méthode de leurs vieux parens. Une nouvelle culture leur demanderoit une étude fatigante. […] Mais en vain cultiveroit-on, en vain multiplieroit-on cette denrée salutaire, si le peuple lui-même, si les citoyens les plus pauvres, entêtés d'un préjugé absurde, refusoient, dédaignoient de la consommer. On les a vus, dans les temps de la plus cruelle disette, repousser avec fureur la pomme de terre, et crier qu'on les vouloit empoisonner.)
=== Pharmacokinetics === While apomorphine has lower bioavailability when taken orally, due to not being absorbed well in the GI tract and undergoing heavy first-pass metabolism, it has a bioavailability of 100% when given subcutaneously. It reaches peak plasma concentration in 10–60 minutes. Ten to twenty minutes after that, it reaches its peak concentration in the cerebrospinal fluid. Its lipophilic structure allows it to cross the blood–brain barrier. Apomorphine has a high clearance rate (3–5 L/kg/hr) and is mainly metabolized and excreted by the liver. It is likely that while the cytochrome P450 system plays a minor role, most of apomorphine's metabolism happens via auto-oxidation, O-glucuronidation, O-methylation, N-demethylation, and sulfation. Only 3–4% of the apomorphine is excreted unchanged and into the urine. The half-life is 30–60 minutes, and the effects of the injection last for up to 90 minutes.
== Function == The protein encoded by this gene is a member of the homeodomain family of DNA binding proteins. It regulates gene expression, morphogenesis, and differentiation and it also plays a role in cell cycle progression, particularly at S-phase. Several alternatively spliced transcript variants of this gene have been described, but the full-length nature of some of these variants has not been determined, and the p200 isoform of Cux1 is processed proteolytically to smaller active isoforms, such as p110. Cux1 DNA binding is stimulated by activation of the PAR2/F2RL1 cell-surface G-protein-coupled receptor in fibroblasts and breast-cancer epithelial cells to regulate Matrix metalloproteinase 10, Interleukin1-alpha, and Cyclo-oxygenase 2 (COX2) genes. Multiple reviews have detailed the tissue-specific functions and genetic interactions in Drosophila and the early characterization of the CDP in mammalian cells, expression and activity of CUX1 in the myeloid cell lineage, multiple CUX1 isoforms, modes of DNA binding, early mouse models and cell-based assays, roles of CUX1 in kidney development and homeostasis, mechanisms by which CUX1 stimulates cell migration and invasion, roles of CUX1 and CUX2 in neurons of the cortex upper layer and the paradoxical implications of CUX1 in cancer. In addition, a number of commentaries present more specific views and speculations.
Sources: en.wikipedia.org
The derivative is drained and salted to taste. Gjiza can be served immediately or refrigerated for a couple of days. In Mexico, chongos zamoranos is a dessert prepared with milk curdled with sugar and cinnamon. In England, milk treated with rennet is referred to as junket, having a texture similar to pudding or jelly. Junket is a pudding-like dessert decorated with ingredients such as semolina, raisins, chopped nuts and other ingredients. This can be baked, or the curd pudding can be used to bake thin custard pancakes.
Retrospective tests collected within the Chinese surveillance system revealed no clear indication of substantial unrecognised circulation of SARS‑CoV‑2 in Wuhan during the latter part of 2019. A meta-analysis from November 2020 estimated the basic reproduction number (
=== Gastrointestinal === Diarrhoea that is characteristic of coeliac disease is chronic, sometimes pale, of large volume, and abnormally foul in odour. Other symptoms of coeliac disease include abdominal pain, cramping, bloating with abdominal distension, and mouth ulcers. As the bowels become more damaged, lactose intolerance can develop.
== Characterization == Characterization techniques for copolymers are similar to those for other polymeric materials. These techniques can be used to determine the average molecular weight, molecular size, chemical composition, molecular homogeneity, and physiochemical properties of the material. However, given that copolymers are made of base polymer components with heterogeneous properties, this may require multiple characterization techniques to accurately characterize these copolymers. Spectroscopic techniques, such as nuclear magnetic resonance spectroscopy (NMR), infrared spectroscopy (IR), and UV spectroscopy, are often used to identify the molecular structure and chemical composition of copolymers. NMR can be used to determine a number of polymer characteristics, including tacticity and repeat unit sequence, predominantly using 1H and 13C NMR. NMR can also be used for analysis of the end groups and branching points within polymer chains, which can provide information both about size and branching pattern. IR spectroscopy is primarily used to identify functional groups attached to a copolymer, but it can also provide information about the degree of branching within a copolymer. UV spectroscopy can be used to determine the concentration of a chromophore-containing monomer within a polymer resin. UV spectroscopy is commonly used as a detector with size-exclusion chromatography. Scattering techniques, such as static light scattering, dynamic light scattering, and small-angle neutron scattering, can determine the molecular size and weight of the synthesized copolymer.
The majority of toxic chemicals found in e-cigarette vapor are below 1% of the corresponding levels permissible by workplace exposure standards, but the threshold limit values for workplace exposure standards are generally much higher than levels considered satisfactory for outdoor air quality. Some chemicals from exposures to the e-cigarette vapor could be higher than workplace exposure standards. A 2018 PHE report stated that the toxicants found in e-cigarette vapor are less than 5% and the majority are less than 1% in comparison with traditional cigarettes. Although several studies have found lower levels of carcinogens in e-cigarette aerosol compared to smoke emitted by traditional cigarettes, the mainstream and second-hand e-cigarette aerosol has been found to contain at least ten chemicals that are on California's Proposition 65 list of chemicals known to cause cancer, birth defects, or other reproductive harm, including acetaldehyde, benzene, cadmium, formaldehyde, isoprene, lead, nickel, nicotine, N-Nitrosonornicotine, and toluene. Free radicals produced from frequent e-cigarette use is estimated to be greater than compared to air pollution. E-cigarette vapor can contain a range of toxicants, and since they have been be used in methods unintended by the producer such as dripping or mixing liquids, this could result in generating greater levels of toxicants.
Sources: en.wikipedia.org
Ester local anesthetics are metabolized by pseudocholinesterases which in people with myasthenia gravis taking anticholinesterase drugs may lead to excessive levels of these ester anesthetics. Amide local anesthetics are not metabolized by psuedocholineesterases. Based on these considerations, amide local anesthetics are strongly preferred over ester local anesthetics in people with myasthenia gravis. Other Drugs: Rare cases of myasthenia gravis exacerbations have been reported in people treated with: 1) penicillins, i.e., ampicillin and amoxicillin; 2) anti-cancer medications, i.e., lorlatinib, nilotinib, imatinib (these three drugs are tyrosine kinase inhibitors that may also cause myasthenia gravis), dabrafenib, and trametinib; 3) antipsychotic drugs, i.e., chlorpromazine, pimozide, thioridazine, clozapine, olanzapine, haloperidol, quetiapine, and risperidone; 4) IFN-α (may also cause myasthenia gravis); and 5) the chemical element, lithium. These agents can be used in people with myasthenia gravis because reports on their exacerbation (or induction) of myasthenia gravis are rare.
1993/695) Guy's and Lewisham National Health Service Trust Dissolution Order 1993 (S.I. 1993/696) Barts National Health Service Trust Dissolution Order 1993 (S.I. 1993/697) King's Healthcare National Health Service Trust (Establishment) Amendment Order 1993 (S.I. 1993/698)
== Society and culture == Melarsoprol is produced by Sanofi and under an agreement with the WHO, it donates melarsoprol to countries where the disease is common. Melarsoprol was used to treat a patient with second-stage African trypanosomiasis on season 1 episode 7 "Fidelity" of the medical drama House MD.
Coca paste (paco, basuco, oxi, pasta) is a crude extract of the coca leaf which contains 40% to 91% cocaine freebase along with companion coca alkaloids and varying quantities of benzoic acid, methanol, and kerosene. The caustic reactions associated with the local application of coca paste prevents its use by oral, intranasal, mucosal, intramuscular, intravenous or subcutaneous routes. Coca paste can only be smoked when combined with a combustible material such as tobacco or cannabis. Crude cocaine preparation intermediates are marketed as cheaper alternatives to pure cocaine to local markets while the more expensive end product is exported to United States and European markets. Freebase cocaine paste preparations can be smoked. The psychological and physiological effects of the paco are quite severe. Media usually report that it is extremely toxic and addictive. According to a study by Intercambios, media appear to exaggerate the effects of paco. These stereotypes create a sense that nothing can be done to help a paco addict and thus stand in the way of rehabilitation programs.
Sources: en.wikipedia.org
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.
Both are synthetic melanocortin agonists and share a similar peptide backbone, but they are distinct molecules with different receptor profiles. Melanotan II was never approved as a medicine, whereas bremelanotide was. Findings about one compound should not be transferred to the other without direct evidence.
It is typically distributed as a lyophilized powder in sealed vials, sometimes with a separate solvent. Purity statements usually originate from the supplier rather than an independent laboratory. Storage recommendations vary between vendors, which makes comparison across sources difficult.
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.